

Ms Bourke
Public Safety
Investment, Place and Opportunity
London Borough of Camden

5 Pancras Square
London
N1C 4AG

13 February 2026

Dear Ms Bourke,


Thank you for your Regulation 28 report dated 22 January 2026 concerning the death of Mr Clive Mark Hyman. Please accept our sincere condolences to Mr Hyman's family for their tragic loss. We appreciate being notified and for the thoroughness of your investigation.

The Association of the British Pharmaceutical Industry (ABPI) is a trade association representing the research-based biopharmaceutical industry in the UK. The ABPI is not a marketing authorisation holder for medicinal products, and it does not have statutory licensing or labelling authority for medicines. This regulatory responsibility sits with the Medicines and Healthcare products Regulatory Agency (MHRA), whom I note you have also sent this Regulation 28 report to. Decisions on statutory labelling, approved patient information leaflets (PILs) and licence changes are for the MHRA and the marketing authorisation holder(s).

Because the coroner's matters principally concern (a) clinical guidance for head injury and (b) patient-facing safety information and labelling for apixaban, and because the MHRA is the statutory regulator for licensing and labelling, ABPI itself has no regulatory levers to change product leaflets or labelling for individual medicines.

We have however made the originator company, Bristol Myers Squibb (BMS), aware of your report and the coroner's concerns so they can consider any appropriate action regarding product information and patient materials.

Yours sincerely,



Chief Executive
Association of the British Pharmaceutical Industry